DasatinibandQuercetinSenolyticTherapy

Why It Matters

The accumulation of senescent cells is implicated in a vast array of age-related diseases, affecting over 80% of individuals over 65 and contributing to healthcare costs exceeding $1 trillion annually in the US alone. Imagine a future where a periodic senolytic treatment, perhaps an annual pill regimen, helps maintain youthful tissue function, reducing the incidence of arthritis, heart disease, and neurodegeneration. Pharmaceutical companies developing senolytics stand to win immensely, while traditional palliative care providers for chronic age-related diseases might see a shift in demand. The main barriers include ensuring tissue-specificity, minimizing off-target effects, and navigating stringent regulatory approval for aging as a 'treatable condition.' Realistic timelines suggest early targeted therapies could be available within 5-10 years, with broader applications taking 15-20 years, with companies like Unity Biotechnology and Alkahest leading the race. A less obvious consequence could be a significant increase in global population numbers and an altered social structure around retirement and productivity.